First-line atezolizumab/durvalumab plus platinum-etoposide combined with radiotherapy in extensive-stage small-cell lung cancer.

BMC Cancer · 2023 · PMC10080806 · PMID 37024843

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

near-significantp = 0.051so close (0.05 < p ≤ 0.1)

In the subgroup analysis, treatment response CR/PR group compared with SD showed near-significant longer PFS (13.7 vs. 7.7 months, p = 0.051) and OS (not reached vs. 13.4 months, p = 0.088).

also in 397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.